Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Study of FK949E in Elderly Bipolar Patients
NCT01737268Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2012
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of quetiapine (extended-release tablet, brand name: Bipresso) in bipolar disorder (BD), sponsored by Astellas Pharma. Primary endpoint: Montgomery-Asberg Depression Rating Scale Total Score at 52 weeks. Started Oct 2012; status: completed.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT01737268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01737268.